Key result
Low-molecular-weight dextran administration did not interfere with pretransfusion compatibility testing in any instance, even at high serum levels.
Why the study?
Does low-molecular-weight dextran administration interfere with pretransfusion compatibility testing in patients with vascular disorders?
Cohort (n=24)
Does low-molecular-weight dextran administration interfere with pretransfusion compatibility testing in patients with vascular disorders?
Low-molecular-weight dextran administration does not appear to interfere with pretransfusion compatibility testing.
No interference seen with dextran in compatibility testing; leaves open validation in larger, diverse cohorts.
The effects of dextran therapy on pretransfusion compatibility testing were evaluated in 24 patients with a variety of vascular disorders. Specimens were drawn before, during, and after the administration of low-molecular-weight dextran (average molecular weight, 40 kd). Forty-three specimens were studied extensively with several immunohematologic techniques. Dextran levels were measured to determine whether the concentration influenced the results of serologic tests. In no instance could we demonstrate any interference by dextran with pretransfusion tests, even at high serum levels of dextran.
No takes yet. Share an insight, caveat, or question.
Bartholomew et al. (1986) conducted a cohort in Vascular disorders (n=24). Low-molecular-weight dextran vs. Baseline (before administration) was evaluated on Interference with pretransfusion compatibility testing. Low-molecular-weight dextran administration did not interfere with pretransfusion compatibility testing in any instance, even at high serum levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: